650 related articles for article (PubMed ID: 16597510)
1. Yellow fever vaccine-associated viscerotropic disease and death in Spain.
Doblas A; Domingo C; Bae HG; Bohórquez CL; de Ory F; Niedrig M; Mora D; Carrasco FJ; Tenorio A
J Clin Virol; 2006 Jun; 36(2):156-8. PubMed ID: 16597510
[TBL] [Abstract][Full Text] [Related]
2. Yellow fever-associated viscerotropic disease in Barcelona, Spain.
Muñoz J; Vilella A; Domingo C; Nicolas JM; de Ory F; Corachan M; Tenorio A; Gascon J
J Travel Med; 2008; 15(3):202-5. PubMed ID: 18494699
[TBL] [Abstract][Full Text] [Related]
3. Viscerotropic disease following yellow fever vaccination in Peru.
Whittembury A; Ramirez G; Hernández H; Ropero AM; Waterman S; Ticona M; Brinton M; Uchuya J; Gershman M; Toledo W; Staples E; Campos C; Martínez M; Chang GJ; Cabezas C; Lanciotti R; Zaki S; Montgomery JM; Monath T; Hayes E
Vaccine; 2009 Oct; 27(43):5974-81. PubMed ID: 19679215
[TBL] [Abstract][Full Text] [Related]
4. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe.
Bae HG; Domingo C; Tenorio A; de Ory F; Muñoz J; Weber P; Teuwen DE; Niedrig M
J Infect Dis; 2008 Jun; 197(11):1577-84. PubMed ID: 18419548
[TBL] [Abstract][Full Text] [Related]
5. [Yellow fever].
Wiercińska-Drapało A
Przegl Epidemiol; 2004; 58 Suppl 1():101-5. PubMed ID: 15807166
[TBL] [Abstract][Full Text] [Related]
6. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004.
Vellozzi C; Mitchell T; Miller E; Casey CG; Eidex RB; Hayes EB
Am J Trop Med Hyg; 2006 Aug; 75(2):333-6. PubMed ID: 16896144
[TBL] [Abstract][Full Text] [Related]
7. Acute viscerotropic disease following vaccination against yellow fever.
Hayes EB
Trans R Soc Trop Med Hyg; 2007 Oct; 101(10):967-71. PubMed ID: 17669451
[TBL] [Abstract][Full Text] [Related]
8. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.
Kitchener S
Vaccine; 2004 Jun; 22(17-18):2103-5. PubMed ID: 15149765
[TBL] [Abstract][Full Text] [Related]
9. Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):989-93. PubMed ID: 12455906
[TBL] [Abstract][Full Text] [Related]
10. Review of the risks and benefits of yellow fever vaccination including some new analyses.
Monath TP
Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
[TBL] [Abstract][Full Text] [Related]
11. A case suspected for yellow fever vaccine-associated viscerotropic disease in the Netherlands.
van de Pol EM; Gisolf EH; Richter C
J Travel Med; 2014; 21(6):421-4. PubMed ID: 24920138
[TBL] [Abstract][Full Text] [Related]
12. Yellow fever vaccination: some thoughts on how much is enough [Vaccine 23 (2005) 3908-3914].
Martins RM; Galler R; Freire MS; Camacho LA; de Lourdes S Maia M; Homma A
Vaccine; 2007 Jan; 25(1):10-1. PubMed ID: 16448728
[TBL] [Abstract][Full Text] [Related]
13. [Yellow fever vaccination: update on rare and severe adverse effects].
Receveur MC; Bruyand M; Pistone T; Malvy D
Med Mal Infect; 2009 Apr; 39(4):234-41. PubMed ID: 19167852
[TBL] [Abstract][Full Text] [Related]
14. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.
Khromava AY; Eidex RB; Weld LH; Kohl KS; Bradshaw RD; Chen RT; Cetron MS;
Vaccine; 2005 May; 23(25):3256-63. PubMed ID: 15837230
[TBL] [Abstract][Full Text] [Related]
15. First case of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) in Hong Kong.
Leung WS; Chan MC; Chik SH; Tsang TY
J Travel Med; 2016 Apr; 23(4):. PubMed ID: 27087559
[TBL] [Abstract][Full Text] [Related]
16. Rare case of fatal yellow fever vaccine-associated viscerotropic disease.
Gerasimon G; Lowry K
South Med J; 2005 Jun; 98(6):653-6. PubMed ID: 16004173
[TBL] [Abstract][Full Text] [Related]
17. Yellow fever: epidemiology and prevention.
Barnett ED
Clin Infect Dis; 2007 Mar; 44(6):850-6. PubMed ID: 17304460
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil.
Engel AR; Vasconcelos PF; McArthur MA; Barrett AD
Vaccine; 2006 Apr; 24(15):2803-9. PubMed ID: 16464518
[TBL] [Abstract][Full Text] [Related]
19. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
[TBL] [Abstract][Full Text] [Related]
20. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
